TABLE 1.
Values of input parameters in base model
| Input parameters | Value | Reference |
|---|---|---|
| Number in cohort | 100,000 | |
| Life expectancy at 18 years | 60.5 years | (28) |
| Quality adjusted life expectancy at 18 years | 50.1 years | (29) |
| Lifetime earnings | $2,139,000* | (30) |
| IMD cumulative incidence age 18 to 21 years | 6.5 cases per 100,000†‡ | Health Canada, written communication |
| IMD cumulative incidence age 22 to 27 years | 2.8 cases per 100,000† | Health Canada, written communication |
| Proportion serogroup C | 55%† | Health Canada, written communication |
| Proportion serogroups A, W-135 and Y | 10%† | Health Canada, written communication |
| Disease costs | $27,000 per case | (31) |
| Case fatality rate | 11% | (18) |
| Sequelae rate in survivors | 20% | (18) |
| Quality of life of survivors with sequelae | 72% | (32) |
| Productivity of survivors with sequelae | 80% | (32) |
| Polysaccharide vaccine efficacy first year | 90% | (33) |
| Polysaccharide vaccine efficacy decrease | 10% per year | Expert opinion |
| Polysaccharide vaccine purchase price | $35 per dose§ | Quebec Ministry of Health, written communication |
| Conjugate vaccine efficacy first years | 90% | (20) |
| Conjugate vaccine efficacy decrease | 1% per year | Expert opinion |
| Conjugate vaccine purchase price | $50 per dose§ | Quebec Ministry of Health, written communication |
| Cost of adverse reactions | $0.03 per dose | (31) |
| Program coverage of target population | 50% | Expert opinion |
| Vaccine administration cost | $24.59 per dose¶ | (34) |
| Discounting rate | 3% per year | (35) |
*
Two times the lifetime average earning of Canadians
†
Invasive meningococcal disease (IMD) surveillance data for the period from 1995 to 1998
‡
Assuming half of cases occurring during first year
§
Purchase price for the public health system
¶
Vaccine given alone in medical clinics